The vaccine was found to produce both antibodies and virus-killing T cells.
Fatigue and headache were the most common side effects reported by the 1,077 study participants, all adults.
"A vaccine later this year is not impossible, a lot of things would have to go right for that to happen and to be deployed in 2020, but we’re still targeting that."
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Oxford coronavirus vaccine generates promising Phase 1/2 results: StudyA team of scientists at the University of Oxford released promising results showing their COVID-19 vaccine appears safe in an early-stage study — welcome news for one of the most advanced vaccine programs in the world. The Phase 1/2 results, published Monday in the scientific journal The Lancet, also
Read more »
Promising Sign As Coronavirus Vaccine Developed By AstraZeneca And Oxford University Appears Safe, Early Trials ShowThe vaccine is still in early-stage clinical trials, and it is yet to be seen whether it can protect people against the virus.
Read more »
Oxford University, AstraZeneca Covid-19 Vaccine Front-Runner Shows Promise in TrialsA leading coronavirus-vaccine candidate being developed by University of Oxford researchers and AstraZeneca showed positive results in early trials, according to published results, raising the prospect that a shot could be available by the end of this year.
Read more »
Oxford coronavirus vaccine generates promising Phase 1/2 results: Study
Read more »
Coronavirus vaccine from Oxford and AstraZeneca shows positive response in early trialA potential coronavirus vaccine developed by Oxford University in the U.K. has produced an immune response in an early-stage human trial, according to newly released data published Monday in medical journal The Lancet.
Read more »
Oxford vaccine trial shows ‘double immunity’ against COVID-19Oxford University released the results of its phase 1 trial, and found the vaccine creates double immunity antibody cells. They are now ready to move forward with more aggressive testing, including clinical trials in the United States.
Read more »